| Title: | Joint associations of accelerometer-measured physical activity and cardiovascular-kidney-metabolic syndrome stages with the risks of cancer and all-cause mortality |
| Journal: | Journal of the National Cancer Institute |
| Published: | 17 Dec 2025 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/41408084/ |
| DOI: | https://doi.org/10.1093/jnci/djaf365 |
Publication 17118
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BACKGROUND: Cardiovascular-kidney-metabolic (CKM) syndrome significantly increases cancer and mortality risks, but the combined effects of CKM syndrome and physical activity (PA) on these outcomes remain poorly understood.</p>
METHODS: This prospective study included 66,650 UK Biobank participants with accelerometry data. CKM syndrome was classified into five stages based on metabolic, kidney, and cardiovascular health. PA was categorized by intensity into light (LPA), moderate (MPA), vigorous (VPA), and moderate-to-vigorous (MVPA) levels, and further divided into tertiles by daily duration. Multivariable Cox models were used to estimate hazard ratios.</p>
RESULTS: Over a median follow-up of 8.03 years, 4,301 incident cancer cases and 2,442 deaths occurred. Advancing CKM stages were associated with elevated risks of both cancer incidence and all cause mortality, while increasing PA levels reduced these risks. Significant interactions were observed between CKM syndrome and both MPA and MVPA on cancer and mortality risks (P interaction < 0.05). In participants with the lowest tertile of MPA or MVPA, those in stages 2 and 4 had higher cancer risk, while in the highest tertile, this risk was no longer elevated. For all-cause mortality, in participants with the lowest tertile of MPA or MVPA, CKM stage 3 exhibited higher risks, while those in the highest tertile did not. CKM stage 4 remained associated with higher mortality across all PA intensity levels, but risks decreased with increasing MVPA levels.</p>
CONCLUSIONS: Higher levels of MPA and MVPA may mitigate the elevated risks of both cancer incidence and all-cause mortality associated with CKM stages 2 to 4.</p>
12 Authors
- Jia-Cheng Liu
- Rui Yang
- Zan-Fei Feng
- Bang-Quan Liu
- Yu Li
- Yu-Han Chen
- Dong-Run Li
- Wen-Rui Zheng
- Ning Liu
- Shan-Yan Gao
- Qi-Jun Wu
- Ting-Ting Gong
1 Application
| Application ID | Title |
|---|---|
| 211772 | Understanding the role of modifiable and genetic factors with sarcopenia in UK biobank: a longitudinal analysis |
Enabling scientific discoveries that improve human health